Stock A006620 DONGKOO BIO & PHARMA CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News DongKoo Bio & Pharma Co., Ltd.

Equities

A006620

KR7006620009

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 28/05/2024 BST 		5-day change 1st Jan Change
6,760 KRW -2.87% Intraday chart for DongKoo Bio & Pharma Co., Ltd. -8.15% +19.43%
05-17 Qurient Co., Ltd. announced that it has received KRW 13.499996307 billion in funding from DongKoo Bio & Pharma Co., Ltd. CI
05-02 Tranche Update on DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback Plan announced on November 2, 2023. CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Qurient Co., Ltd. announced that it has received KRW 13.499996307 billion in funding from DongKoo Bio & Pharma Co., Ltd.
CI
Tranche Update on DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback Plan announced on November 2, 2023.
CI
Tranche Update on DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback Plan announced on November 2, 2023.
CI
DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback announced on November 2, 2023, has expired with 321,701 shares, representing 1.17% for KRW 1,998.73 million.
CI
Qurient Co., Ltd. announced that it expects to receive KRW 13.499998256 billion in funding from DongKoo Bio & Pharma Co., Ltd. and another investor
CI
OTOM Co., Ltd. announced that it has received KRW 2 billion in funding from DongKoo Bio & Pharma Co., Ltd.
CI
HDT Co., Ltd announced that it expects to receive KRW 2 billion in funding from DongKoo Bio & Pharma Co., Ltd.
CI
Tranche Update on DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback Plan announced on November 2, 2023.
CI
DongKoo Bio & Pharma Co., Ltd. announces an Equity Buyback for KRW 2,000 million worth of its shares.
CI
DongKoo Bio&Pharma Co., Ltd. authorizes a Buyback Plan.
CI
DongKoo Bio & Pharma Co., Ltd.(KOSDAQ:A006620) dropped from S&P Global BMI Index
CI
DongKoo Bio & Pharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
HLB Pharmaceutical Co., Ltd announced that it has received KRW 20 billion in funding from JW Holdings Corporation, Prime Life & Health Co., Ltd., DongKoo Bio & Pharma Co., Ltd.
CI
HLB Pharmaceutical Co., Ltd announced that it expects to receive KRW 20 billion in funding from JW Holdings Corporation, Prime Life & Health Co., Ltd., DongKoo Bio & Pharma Co., Ltd.
CI
Tranche Update on DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback Plan announced on January 28, 2022.
CI
Tranche Update on DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback Plan announced on January 28, 2022.
CI
DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback announced on January 28, 2022, has expired with 416,327 shares, representing 1.49% for KRW 2,995.1 million.
CI
Tranche Update on DongKoo Bio&Pharma Co., Ltd.'s Equity Buyback Plan announced on January 28, 2022.
CI
Tranche Update on DongKoo Bio&Pharma Co., Ltd.'s Equity Buyback Plan announced on October 14, 2021.
CI
DongKoo Bio&Pharma Co., Ltd.'s Equity Buyback announced on October 14, 2021, has expired with 251,612 shares, representing 0.89% for KRW 1,997.79 million.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A006620 Stock
  4. News DongKoo Bio & Pharma Co., Ltd.